Exenatide vs Mazdutide

Exenatide is a GLP-1 receptor agonist already approved by the FDA to treat type 2 diabetes, available as Byetta or Bydureon. Mazdutide, still in development, is a dual GLP-1 and glucagon receptor agonist that has not yet received FDA approval for any use. Exenatide is taken as an injection, while details on how Mazdutide would be administered have not been provided.

AI summary of the sources below.